DCM
ANAB icon

DAFNA Capital Management’s AnaptysBio ANAB Stock Holding History

DAFNA Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,500
Closed -$132K – 75
2017
Q2 		$132K Buy
5,500
+1,000
+22% +$25.1K 0.09% 71
2017
Q1 		$125K Buy
+4,500
New +$105K 0.11% 69

Other funds holding ANAB

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DAFNA Capital Management's ANAB Position: Q3 2017 in Review

DAFNA Capital Management sold out of AnaptysBio (ANAB) in Q3 2017, closing a stake of 5,500 shares — an estimated $132K sold.

DAFNA Capital Management first reported a position in ANAB in Q1 2017 and held it in 2 quarters. The position peaked at $132K in Q2 2017. 71 funds tracked by Wall St. Rank hold ANAB as of Q3 2017.

  • DAFNA Capital Management reported no remaining AnaptysBio position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 5,500 AnaptysBio shares in Q3 2017, an estimated $132K.
  • DAFNA Capital Management first reported a position in AnaptysBio in Q1 2017 and held it in 2 quarters.
  • DAFNA Capital Management's AnaptysBio position peaked at $132K in Q2 2017.
  • 71 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.